Paul Vincent Holland

Paul Vincent Holland's AcademicInfluence.com Rankings

Philosophy

#8106

World Rank

#11426

Historical Rank

Logic

#5139

World Rank

#6510

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Paul Vincent Holland's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is Paul Vincent Holland Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Paul Vincent Holland's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Transfusion-related acute lung injury: report of a clinical look-back investigation. (2002) (415)
Transfusion‐associated hepatitis not due to viral hepatitis type A or B † (1975) (390)
TRANSMISSIBLE AGENT IN NON-A, NON-B HEPATITIS (1978) (374)
Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. (1976) (367)
CLINICAL AND SEROLOGICAL ANALYSIS OF TRANSFUSION-ASSOCIATED HEPATITIS (1975) (347)
Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. (1972) (320)
Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. (1986) (317)
Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. (1978) (275)
Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. (1999) (269)
Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. (1981) (259)
Donor transaminase and recipient hepatitis. Impact on blood transfusion services. (1981) (250)
The natural history of transfusion-associated infection with human immunodeficiency virus. Factors influencing the rate of progression to disease. (1989) (239)
Evaluation of assays for antibody to hepatitis E virus by a serum panel (1998) (235)
HLA class II antibodies in transfusion‐related acute lung injury (2001) (234)
Noninfectious serious hazards of transfusion. (2002) (213)
TRALI: correlation of antigen‐antibody and monocyte activation in donor‐recipient pairs (2003) (202)
The prevalence of hepatitis C virus antibodies among hemodialysis patients. (1990) (176)
Increased detection of hepatitis C virus (HCV)‐infected blood donors by a multiple‐antigen HCV enzyme immunoassay (1992) (168)
Irradiation of blood products. Indications and guidelines (1985) (164)
NON-A, NON-B POST-TRANSFUSION HEPATITIS (1977) (156)
A complement-fixation test for measuring Australia antigen and antibody. (1969) (156)
A comparison of the frequency of hepatitis-B antigen and antibody in hospital and nonhospital personnel. (1973) (146)
Prevalence of and risk factors for antibody to hepatitis E virus seroreactivity among blood donors in Northern California. (1997) (143)
Growth of bacteria in inoculated platelets: implications for bacteria detection and the extension of platelet storage (2000) (133)
Hepatitis B, hepatitis C and HIV transfusion‐transmitted infections in the 21st century (2011) (131)
Transmission of hepatitis B to chimpanzees by hepatitis B surface antigen-positive saliva and semen (1977) (130)
Transfusion-associated hepatitis not due to viral hepatitis type A or B. 1975. (1975) (127)
Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. (1993) (114)
Alloimmunization in two multitransfused patient populations (1981) (110)
Prevalence of human immunodeficiency virus type 1 p24 antigen in U.S. blood donors - An assessment of the efficacy of testing in donor screening (1990) (110)
Biophysical Properties of Australia Antigen (1969) (107)
Radioimmunoassay for the detection of the core of the Dane particle and antibody to it. (1974) (106)
Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test (2005) (104)
Australia Antigen: Large-Scale Purification from Human Serum and Biochemical Studies of Its Proteins (1971) (101)
High‐level long‐term white blood cell microchimerism after transfusion of leukoreduced blood components to patients resuscitated after severe traumatic injury (2005) (97)
A second-generation method of genotyping hepatitis C virus by the polymerase chain reaction with sense and antisense primers deduced from the core gene. (1996) (94)
Hepatitis B virus blood screening: unfinished agendas (2006) (92)
Differentiation of hepatitis B virus genotypes D and E by ELISA using monoclonal antibodies to epitopes on the preS2-region product. (2000) (88)
Health-care workers positive for hepatitis B surface antigen. Are their contacts at risk? (1975) (88)
Seroepidemiology of viral infections among intravenous drug users in northern California. (1992) (87)
Clinical outcomes of ABO-incompatible RBC transfusions. (2008) (85)
Risk of human immunodeficiency virus infection from blood donors who later developed the acquired immunodeficiency syndrome. (1987) (85)
Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. (1999) (82)
Transfusion-Related Acute Lung Injury Report of a Clinical LookBack Investigation (2002) (82)
Microtiter solid-phase radioimmunoassay for hepatitis B antigen. (1973) (82)
Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. (2001) (79)
Non-A, non-B hepatitis and antibody to hepatitis C virus. (1990) (77)
Transfusion‐associated graft‐versus‐host disease (2008) (77)
The emerging pattern of post-transfusion hepatitis. (1975) (76)
Counterelectrophoresis for detection of hepatitis--associated antigen: methodology and comparison with gel diffusion and complement fixation. (1971) (74)
The development of HBsAg-positive hepatitis despite the previous existence of antibody to HBsAg. (1976) (73)
Genotyping hepatitis C virus isolates from Spain, Brazil, China, and Macau by a simplified PCR method (1996) (67)
Hepatitis B antigen: regional variation in incidence and subtype ratio in the American Red Cross donor population. (1973) (66)
Antibody to hepatitis-associated antigen. Frequency and pattern of response as detected by radioimmunoprecipitation. (1972) (65)
Comparison of X‐ray vs. gamma irradiation of CPDA‐1 red cells (2005) (65)
Subtyping of hepatitis-associated antigen (HB-Ag); simplified technique with counterelectrophoresis. (1972) (64)
Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus (1991) (62)
Blood transfusion is associated with donor leukocyte microchimerism in trauma patients. (2004) (59)
Anaphylactic reactions to IgA: a difficult transfusion problem. (1970) (58)
Seroepidemiological studies of transfusion-associated hepatitis. (1971) (57)
Platelet bacterial contamination and the use of a chemiluminescence‐ linked universal bacterial ribosomal RNA gene probe (1994) (57)
Pathogenesis of the acute renal failure associated with incompatible transfusion. (1967) (56)
Isoimmunization after multiple transfusions. (1966) (56)
Biophysical characterization of the adr subtype of hepatitis B antigen and preparation of anti-r sera in rabbits. (1975) (55)
Peripheral‐blood mononuclear cell responses to recombinant hepatitis C virus antigens in patients with chronic hepatitis C (1993) (52)
Prevention of transfusion-associated graft-vs-host disease. (1989) (52)
Failure of Australia antibody to prevent post-transfusion hepatitis. (1969) (51)
Screening of blood donors for idiopathic CD4+ T‐lymphocytopenia (1994) (50)
Circannual variation in lymphocyte subsets, revisited (1994) (49)
Relation of hepatitis-B-antigen subtypes in symptom-free carriers to geographical origin and liver abnormalities. (1973) (49)
Significance of antibody to hepatitis B core antigen in blood donors as determined by their serologic response to hepatitis B vaccine (1993) (49)
Post-transfusion hepatitis C virus infection. (1992) (48)
Distribution of Hepatitis B Virus Genotypes among American Blood Donors Determined with a PreS2 Epitope Enzyme-Linked Immunosorbent Assay Kit (2002) (48)
Viral infections and the blood supply. (1996) (46)
Mechanisms of severe transfusion reactions. (2001) (46)
Infectious disease testing for blood transfusions. NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions. (1995) (45)
Transmission of hepatitis B virus infection by transfusion of frozen-deglycerolized red blood cells. (1978) (44)
The Viral Activation Transfusion Study (VATS): rationale, objectives, and design overview (1996) (44)
Visual assessment of hemolysis in red blood cell units and segments can be deceptive (2004) (43)
Detection of acute hepatitis C virus infection by ELISA using a synthetic peptide comprising a structural epitope. (1992) (41)
Microchimerism in transfused trauma patients is associated with diminished donor-specific lymphocyte response. (2005) (41)
Preparation and characterization of complement-fixing hepatitis-associated antigen and antiserum. (1970) (41)
Risk of transfusing blood containing antibody to hepatitis-B surface antigen. (1974) (40)
Prolonged circulation of activated platelets following plasmapheresis (1994) (38)
THE HEPATOPATHY OF HYPERNEPHROMA. (1965) (37)
Prevalence of antibody to hepatitis C virus in a blood donor population (1991) (36)
The Duffy blood group phenotype in American blacks infected with Plasmodium vivax in Vietnam. (1978) (35)
Delayed hemolytic transfusion reaction with acute renal failure. (1968) (34)
Detection of plasmapheresis‐induced platelet activation using monoclonal antibodies (1992) (33)
Early diagnosis and successful treatment of a patient with transfusion‐associated GVHD with autologous peripheral blood progenitor cell transplantation (2002) (32)
γ-Globulin in the Prophylaxis of Posttransfusion Hepatitis (1966) (32)
Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assays (2002) (32)
Accelerated immune red cell destruction in the absence of serologically detectable alloantibodies (1980) (30)
Hepatitis C virus in blood samples from volunteer donors (1993) (30)
Chronic hepatitis B virus infection in an anti‐HBC–nonreactive blood donor: Variant virus or defective immune response? (1992) (30)
The Clinical Significance of Anti‐H in an Individual with the Oh (Bombay) Phenotype (1978) (29)
Fluctuation of serum HCV‐RNA levels in untreated blood donors with chronic hepatitis C virus infection (2002) (26)
Non-A, non-B viral hepatitis. (1981) (26)
Hepatitis B Antigen (HB Ag) and Antibody (Anti‐HB Ag) in Cold Ethanol Fractions of Human Plasma (1972) (23)
Characterization of a reduction-sensitive factor from human plasma responsible for apparent false activity in competitive assays for antibody to hepatitis B core antigen (1991) (22)
Lyme disease—another transfusion risk? (1989) (22)
Editorial: Hepatitis B immune globulin: Evaluation of clinical trials and rationale for usage. (1975) (21)
The Ausria test: critical evaluation of sensitivity and specificity. (1973) (21)
Universal leukocyte reduction (2000) (21)
False positive tests for hepatitis-associated antigen in blood donors caused by antibodies to ruminant serum proteins. (1972) (21)
Staff costs associated with the implementation of a comprehensive compliance program in a community blood center (1995) (21)
Hepatitis-associated antigen. To test or not to test? (1970) (20)
Evidence of hepatitis in patients receiving transfusions of blood components containing antibody to hepatitis C (1993) (19)
Does it Make Sense for Blood Transfusion Services to Continue the Time-Honored Syphilis Screening with Cardiolipin Antigen? (1981) (18)
Post‐Transfusion Hepatitis: Current Risks and Causes (1998) (18)
Multiple red cell antigen loss in acute granulocytic leukemia (1978) (18)
Indirect tests to detect the non-A, non-B hepatitis carrier state. (1984) (18)
HIV transmissions from a window-period platelet donation. (2001) (18)
Serum agglutinins to commercially prepared albumin. (1971) (17)
Microtiter Solid-Phase Radioimmunoassay for Hepatitis B Antigen (1973) (17)
Posttransfusion hepatitis. (1967) (17)
Evidence of hepatitis in patients receiving transfusions of blood components containing antibody to hepatitis C. (1993) (16)
Delayed hemolytic transfusion reaction caused by anti‐P1 antibody (1981) (16)
Consent for transfusion: is it informed? (1997) (16)
Current risks of viral hepatitis from blood transfusions (1998) (14)
Elevated levels of serum mucin-associated antigen in adult patients with cystic fibrosis. (1993) (14)
Identification of HIV‐infected transfusion recipients: the utility of crossreferencing previous donor records with AIDS case reports (1990) (13)
Donor cell induced CD69 expression and intracellular IL-2 and IL-4 production by peripheral blood lymphocytes isolated from kidney transplant recipients. (1999) (13)
Transfusion-Related Acute Lung Injury—Reply (2002) (13)
Gamma-globulin for hepatitis-virus B. Prevention or extension? (1972) (13)
Changes in peripheral blood CD5 (Bla) B‐cell populations and autoantibodies following blood transfusion (1995) (12)
Toward a coalition against transfusion‐associated GVHD (2003) (12)
Acquisition of K: 1 ‐like antigen during terminal sepsis (1984) (12)
Anti‐HTLV‐III testing of blood donors: reproducibility and confirmability of commercial test kits (1985) (12)
Donor serum alanine aminotransferase activity and the risk of transfusion-associated hepatitis. (1983) (12)
Post-transfusion viral hepatitis and the TTVS. (1981) (12)
The disappearance of transfusion-transmitted hepatitis C virus infections in the United States. (2001) (11)
Comparison of two second‐generation anti‐hepatitis C virus ELISA on 21431 US blood donor samples (1995) (11)
Interpretation of atypical patterns encountered when using a flow cytometry-based method to detect residual leukocytes in leukoreduced red blood cell components. (2002) (11)
Overview: diagnostic tests for viral infections transmitted by blood. (1994) (11)
Do You Think that the Cross Match with Donor Red Cells Can Be Omitted when the Serum of a Patient Has Been Tested for the Presence of Red Cell Alloantihodies with a Cell Panel (1982) (11)
The clinical significance of hepatitis B virus antigens and antibodies. (1975) (10)
Effects of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis (1999) (10)
Passive hemagglutination assay for antibody to subtypes of hepatitis B antigen. (1974) (10)
Based on your analysis of the benefits and costs of routine donor screening for ALT-GPT to reduce the incidence of post-transfusion non-A, non-B hepatitis in your blood services region, what action would you recommend on this matter? (1983) (10)
Hepatitis B antigen subtypes-history, significance and immunogenicity. (1975) (9)
On the rare ayr phenotype of hepatitis B Antigen. (1973) (9)
Idiopathic CD4 + T‐lymphocytopenia (ICL) and the safety of blood transfusions: What do we know and what should we do? (1992) (9)
Questionable efficacy of confidential unit exclusion (1990) (9)
Transfusion Microbiology: Hepatitis viruses (2008) (9)
Evaluation of the Effectiveness of Hepatitis Screening Tests 1 (1971) (9)
Seronegative hepatitis C virus liver failure following transplantation of a cadaveric heart. (1994) (8)
Practical problems for HBSAg subtyping. (1976) (8)
How Far Shall We Go in the Predonation Selection of Blood Donors to Safeguard Patients for Blood‐Transfusion‐Related Infections?: Editorial (1993) (8)
Neutrophils contain cholesterol crystals in transfusion-related acute lung injury (TRALI). (2013) (8)
NOTIFICATION AND COUNSELING OF BLOOD DONORS (1996) (7)
Effects of serial plasmapheresis on serum IgA levels in IgA‐deficient blood donors with IgA‐suppressor T cells (1992) (7)
A Brief History of Blood Transfusion (2007) (7)
Detection of antibody to immunodeficiency viruses by dot immunobinding assay (1992) (7)
Isoimmunization after multiple transfusions (1967) (7)
Hepatitis‐Associated Antigen and Antibody in Cold Ethanol Fractionates of Human Blood (1971) (6)
Simultaneous presence in serum of HBsAg and anti-HBs of different specificities. (1978) (6)
Why a new standard to prevent Creutzfeldt‐Jakob disease (1988) (6)
Delayed hemolytic transfusion reaction caused by anti‐P1 (1981) (6)
Old and new tests: where will it end? (2000) (5)
Which Are the Principal Established or Potential Risks for Donors Undergoing Cytapheresis Procedures and How Can They Be Prevented? 1 (1980) (5)
Viral Hepatitis Markers in Soviet and American Blood Donors (1980) (5)
Gamma-globulin in the prophylaxis of posttransfusion hepatitis. (1966) (5)
Evidence that use of a second‐generation hepatitis C antibody assay prevents additional cases of transfusion‐transmitted hepatitis (1994) (5)
A Data Retrieval System for Blood Donor Information (1965) (5)
Antigenic subtypes of hepatitis B antigen in Panama. (1974) (4)
Detection of antibodies to human immunodeficiency virus type 2 (HIV‐2) in blood donor sera using United States assay methods for anti‐HIV type 1 (1992) (4)
Autoimmune hemolytic anemia, acute leukemia, and carcinoma of the lung. Sodium phosphate P 32 treatment of polycythemia vera. (1967) (4)
The CUE debate (continued): on surrogate tests and surrogate endpoints (1991) (4)
Paid cytapheresis sellers, not donors (1994) (3)
Exposure to a food-handler with hepatitis B. (1972) (3)
The relationship between hepatitis B virus infection and hepatic cell carcinoma in Mozambique. (1977) (3)
Viral hepatitis. Light at the end of the tunnel. (1974) (3)
Comparison of two approved enzyme immunoassays for the detection of antibodies to the hepatitis C virus in 5216 United States blood donors (1992) (3)
The effects of dilution on the outcome of pooled plasma testing with HIV type 1 (HIV‐ 1) RNA genome amplification as compared to the outcome of individual‐unit testing with other HIV‐1 markers (1998) (3)
Discussion of Nomenclature (1976) (3)
Nonspecific test reaction for antibodies to hepatitis B surface antigen in chronic HBAg carriers. (1977) (3)
Evidence‐based medicine in transfusion medicine: an update (2007) (3)
Other Reactions and Alloimmunization (2001) (3)
Hepatitis B virus infection in the Wiskott-Aldrich syndrome. (1976) (3)
Serologic abnormalities in systemic lupus erythematosus associated with viral hepatitis and tuberculosis. (1973) (3)
A study of street heroin lots for the presence of the hepatitis B surface antigen. (1978) (2)
D.N.C.B. test in hepatitis. (1974) (2)
Idiopathic inflammatory myopathy. Failure to detect hepatitis B antigen in serum and muscle. (1973) (2)
Strategies for prevention of viral hepatitis in the United States (1996) (2)
Current status of posttransfusion hepatitis. (1980) (2)
Clinical Reactions to Cryoprecipitated Factor VIII (1971) (2)
Toward Zero Occurrence of Post-transfusion Hepatitis: Summary of a Specialty Session (1994) (2)
Measuring the volume of packed RBCs in donors (2001) (2)
Subtypes of HBsAg in Eastern and South‐Eastern Europe (1977) (2)
Comparison of two preparation techniques for white cell‐poor red cells (1988) (2)
Evaluation of a Non-Invasive Hematocrit Determination Device. (2005) (2)
Transfusion of the HIV-seropositive patient. (1999) (2)
Selling blood vs. donating blood (2008) (2)
Repeated blood donations and erythropoietin levels. (1989) (2)
Putting the cart before the horse (2000) (2)
Hemoglobinuria due to anti-rhw1(Cw.) Observations on enzyme test procedures. (1968) (1)
Comprehensive reimbursement model: an alternative to fee-for-service reimbursement by blood centers. (1997) (1)
[Subtypes of HBs antigen in Poland]. (1976) (1)
Potency evaluation of gamma globulin against posttransfusion hepatitis. (1969) (1)
Hepatitis C VirusinBloodSamples fromVolunteer Donors (1993) (1)
Informed Consent for Transfusion Recipients: How Much is Enough? (1996) (1)
Donor deferral registries: an ineffective system whose time is passed (2007) (1)
Hypercoagulability among pediatric patients with diabetic ketoacidosis: the clot thickens. (2013) (1)
INFECTION AND INFECTION CONTROL (Including Disinfectants) (1975) (1)
MICROCHIMERISM IN TRANSFUSED TRAUMA PATIENTS IS ASSOCIATED WITH DIMINISHED DONOR‐SPECIFIC LYMPHOCYTE RESPONSE: 301 (2004) (1)
[Subtypes of hepatitis B antigen]. (1975) (1)
A Non-Invasive Evaluation of Hemoglobin with a New Optical Sensor. (2006) (1)
Informed consent for transfusions. (1991) (1)
CURRENT STATUS OF TRANSFUSION RELATED HIV IN THE U. S. A. -IMPLICATED FOR BLOOD BANKING PRACTICES (1993) (0)
Prophylaxis of viral hepatitis: transfusion transmitted disease and the hepatitis B vaccine. (1983) (0)
Contents, Vol. 1, 1973 (1973) (0)
Process improvement in transfusion medicine. (1999) (0)
Subject Index, Vol. 1, 1973 (1973) (0)
Reply (1990) (0)
TRALI and transfusion associated volume overload (also called TACO for transfusion associated cardiac overload). (2007) (0)
TRALI: Mechanisms, Management, and Prevention, S Kleinman, MA Popovsky. AABB Press, Bethesda (Md) (2008), (196 pages) (2009) (0)
HLA class I antibody screening technique comparison: EOSIN/CFDA (1992) (0)
B lymphocyte crossmatch technique comparison: Immunogenetic bead/nylon wool (1991) (0)
Pathogen Inactivation of Blood Components , Current Status and its Significance (2010) (0)
Clinical severity score predicts early mortality in Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) (1996) (0)
Reply (2009) (0)
Review of Transfusion Microbiology (2009) (0)
Transfusion-related vCJD: prevention strategies for prion transmission. (2007) (0)
Transfusion‐Associated Graft‐versus‐Host Disease: response to Phipps et al. (2009) (0)
Process Improvement in Transfusion Medicine: One Blood Center's Approach (2009) (0)
H. Klein, D. Anstee. Mollison's blood transfusion in clinical medicine. 11th ed. (2007) (0)
The use of hepatitis B immune globulin (HBIG) in the prevention of hepatitis. (1977) (0)
Plasmapheresis of hepatitis B surface antigen carriers. (1980) (0)
The 90s paradox: QA efforts reduce total quality. (1997) (0)
O.023 Transfusion associated hepatitis B virus infections (2006) (0)
Transfusion transmitted infectious diseases. (1993) (0)
Press Review (1999) (0)
Title Page / Contents / Active Participants / Acknowledgements (1976) (0)
Preparation of monospecific subtyping reagents for hepatitis B surface antigen (HBsAg). (1979) (0)
The American Association of Blood Banks 28th Annual Meeting November 9–14, 1975 The Palmer House, Chicago, Illinois (2009) (0)
Subtypes of HBsAg in North America. (1976) (0)
Technics of HAA detection. (1972) (0)
components containing antibody to hepatitis C Evidence of hepatitis in patients receiving transfusions of blood (2003) (0)
Leukocyte reduction and Creutzfeldt-Jakob disease (0)
Would nucleic acid testing (nat) have prevented hiv transmission from window period platelet donations (2000) (0)
Joint physician-nurse committee ensures safe transfer of tasks. (1982) (0)
Failure to transmit human viral hepatitis types A and B to the congenitally athymic nude mouse. (1977) (0)
Letter: D.N.C.B. test in hepatitis. (1974) (0)
Some approaches to deciding HB Ag (Australia antigen) positivity by counterimmunoelectrophoresis (1974) (0)
32 NonA / Non-B Hepatitis : A Review and Interim Report of an Ongoing Prospective Study (2013) (0)
TRANSFUSION MEDICINE Survival of Donor Leukocyte Subpopulations in Immunocompetent Transfusion Recipients: Frequent Long-Term Microchimerism in Severe Trauma Patients (1999) (0)
State-ofthe-Art Paper Vox (2011) (0)

This paper list is powered by the following services:

Paul Vincent Holland's Academic­Influence.com Rankings

Paul Vincent Holland's Degrees

Why Is Paul Vincent Holland Influential?

Paul Vincent Holland's Published Works

Published Works

Paul Vincent Holland's AcademicInfluence.com Rankings